opened in 2014, the vionnaz site is fully compliant with cgmp standards. it specializes in the development and small-scale production of highly potent active pharmaceutical ingredients, up to category 5—the most stringent category in terms of containment and safety.
the facility features three process development laboratories, a dedicated quality control laboratory, and three production units equipped with reactors up to 30 liters in capacity, preparative chromatography systems, and freeze-dryers up to pilot scale. in particular, the site is capable of producing highly potent components (known as “warheads”) as well as the molecules that link them to an antibody (the “linkers”). together, these enable the manufacture of antibody-drug conjugates (adcs), a cutting-edge technology used in oncology that involves attaching a highly potent drug to an antibody to precisely target cancer cells.
establishment : vionnazfounded : 2014main areas of activity : pharmaceuticalnumber of employees : 700 (in switzerland)website : www.carbogen-amcis.com